Enliven Therapeutics, Inc. (ELVN)
54.32
-1.91
(-3.40%)
USD |
NASDAQ |
Sep 11, 16:00
54.29
-0.03
(-0.06%)
After-Hours: 20:00
Enliven Therapeutics Shareholders Equity (Quarterly) : 895.15M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 895.15M |
| March 31, 2026 | 453.36M |
| December 31, 2025 | 459.60M |
| September 30, 2025 | 476.12M |
| June 30, 2025 | 488.47M |
| March 31, 2025 | 288.30M |
| December 31, 2024 | 309.84M |
| September 30, 2024 | 288.40M |
| June 30, 2024 | 304.93M |
| March 31, 2024 | 317.71M |
| December 31, 2023 | 245.91M |
| September 30, 2023 | 261.75M |
| June 30, 2023 | 278.99M |
| March 31, 2023 | 291.42M |
| Date | Value |
|---|---|
| December 31, 2022 | 90.13M |
| September 30, 2022 | 57.29M |
| June 30, 2022 | 61.36M |
| March 31, 2022 | 72.41M |
| December 31, 2021 | 86.03M |
| September 30, 2021 | 99.37M |
| June 30, 2021 | 64.97M |
| March 31, 2021 | 75.59M |
| December 31, 2020 | 84.44M |
| September 30, 2020 | 94.70M |
| June 30, 2020 | 106.30M |
| March 31, 2020 | 105.19M |
| December 31, 2019 | -48.85M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 1.044M |
| CNBX Pharmaceuticals, Inc. | -2.660M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 562.20M |
| Fulcrum Therapeutics, Inc. | 310.70M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 910.22M |
| Total Liabilities (Quarterly) | 15.07M |
| Debt to Equity Ratio | 0.0017 |
| Current Ratio | 64.07 |
| Net Debt Paydown Yield | -0.01% |